Intact Vascular, Inc. Hires Joseph Griffin as Vice President of Regulatory Affairs and Quality Assurance

Intact Vascular, Inc., today announced the appointment of Joseph C. Griffin to the position of Vice President of Regulatory Affairs and Quality Assurance.

Intact Vascular CEO, Carol Burns, commented, “This year our focus is on obtaining FDA IDE approval for our US clinical trial for the Tack-It Endovascular System™. This is an opportune time to bring in someone of Joe’s caliber to lead this effort. He brings a wealth of medical device knowledge to the Company along with a successful track record of gaining US, EU and other international product approvals.”

Most recently, Mr. Griffin served as Vice President of Regulatory Affairs at Flexible Stenting Solutions, Inc., a subsidiary of Cordis Corporation (NYSE:JNJ). Mr. Griffin joined Flexible Stenting Solutions in March 2008 as a VP and executed various regulatory, quality, clinical and compliance duties leading up to a Cordis acquisition in March 2013. Mr. Griffin has over 30 years of experience in design, development, regulatory compliance and manufacture of numerous leading-edge cardiovascular devices.

Mr. Griffin commented, “I’m enthusiastic about the potential for the Tack-It device to offer a new paradigm in the treatment of peripheral artery disease (PAD) for both above and below the knee procedures, and look forward to contributing to the ultimate goal of FDA approval of this novel technology. The compelling 30 day TOBA EU study data presented at the recent LINC meeting has me very excited about the prospect of gaining device approval here in the US.”

About Intact Vascular

Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System™ is designed to optimize peripheral balloon angioplasty results in the treatment of PAD. This technology will offer physicians a new treatment option for treating PAD which affects 8-12 million in the US. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products. Visit www.intactvascular.com for more information.